ObvioHealth has signed a new global licensing agreement with healthcare and diagnostic software solutions provider Dedalus Group to obtain access to the latter’s data mining technology.

The latest agreement for the global licensing of Dedalus’s technology is an expansion of the strategic collaboration between the companies signed last year. 

The prior collaboration permitted ObvioHealth to assess anonymised analytics of healthcare records of Dedalus. 

Through the latest deal, ObvioHealth will leverage Dedalus’ data mining and analytics tools to carry out its research and that of the partners and sponsors of the company. 

This technology will provide access to ObvioHealth’s own multi-source healthcare data analytics to offer improved clinical trial design and recruitment as well as trends on longitudinal disease and therapies.  

Furthermore, partner sites and their providers could suggest clinical trials to their patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This data will aid them in training artificial intelligence (AI)-powered digital and diagnostic instruments to offer an in-depth assessment of disease states.

The digital research ecosystem of ObvioHealth comprises digital devices and instruments, utilised mainly to carry out decentralised clinical trials. 

The latest agreement will bolster the expertise of ObvioHealth in detecting and assessing disease, comorbidity and therapy patterns that could aid providers with decisions in a real clinical workflow. 

Dedalus Group Life Sciences vice-president Koenraad Batselier said: ‍“We are pleased to provide ObvioHealth with a platform that can harmonise a seamless flow of multi-source data from disparate healthcare applications into a standard compliant and secure ecosystem. 

“By linking data sets semantically and normalising them to an industry standard, we are opening up a whole new market—providing data infrastructure for clinical research in a way that was not previously possible.”

In May this year, ‍ObvioHealth developed two new digital tools to boost precision and reduce the burden on patients/caregivers in paediatric clinical trials.